Inno lia hiv 1 2 score assay

The presence of the p24 HIV core antigen was determined using the INNOTEST HIV Antigen MAb (Fujirebio). The INNO-LIA HIV I/II Score assay (Fujirebio) allowed differentiation and comparison in antibody reactivity to individual HIV antigens. Both assays were performed according to the manufacturers’ instructions.

The INNO-LIA HIV I/II Score assay (Fujirebio) was performed according to the manufacturers’ instructions. Using the band intensity of the three internal standards, antibody reaction to the individual HIV antigens was scored as -, ±, 1+, 2+ or 3+ either visually or by the automated LIRAS reading system (Fujirebio). Antibodies against the integrase protein p31 were considered absent when a score of – or ± was given and present when the score was 1+ or more. For the longitudinal samples, INNO-LIA was performed on serial samples until presence of p31 antibodies was documented. For the samples from selected populations an INNO-LIA was performed in the context of this study, for the cross-sectional samples from newly diagnosed patients the results of the diagnostic assay were used.

Screening for HIV was performed according to national algorithms [18 –21 ]. All four study cities first used the Determine HIV 1/2 assay (Abbott Laboratories, Chiba, Japan). Positive results were confirmed using the Bioline HIV-1/2 3.0 assay (SD, Gyeonggi-do, Republic of Korea) in Abidjan, Bamako, and Ouagadougou, or the First Response HIV-1/2 assay (Premier Medical Corporation, Mumbai, India) in Lomé. Samples with discordant results were tested a third time using the HIV 1/2 Stat-Pak assay (Chembio Diagnostics, New York, USA) in Abidjan, the First Response HIV-1/2 assay (Premier Medical Corporation, Mumbai, India) in Bamako, the Inno-Lia HIV I/II Score assay (Fujirebio, Zwijnaarde, Belgium) in Lomé, or a Western Blot assay in Ouagadougou.